

シンポジウム

文部科学省 橋渡し研究加速ネットワークプログラム

# 平成24年度成果報告会 イノベーションをマーケットへ

主催：公益財団法人 先端医療振興財団

共催：北海道臨床開発機構（北海道大学，札幌医科大学，旭川医科大学），  
東北大学，東京大学，名古屋大学，京都大学，大阪大学，九州大学

（2013年3月2日(土) 於：丸ビルホール）

Ministry of Education, Culture, Sports, Science and Technology  
Translational Research Network Program

## Public Debriefing Session 2012 — Move “Innovation” to the “Market” —

Organized by : Foundation for Biomedical Research and Innovation

Co-organized by : Hokkaido Organization for Translational Research (Hokkaido University,  
Sapporo Medical University, Asahikawa Medical University),  
Tohoku University, The University of Tokyo, Nagoya University,  
Kyoto University, Osaka University, Kyushu University

Saturday, March 2, 2013 Marunouchi Building Hall

### Abstract

The Coordination, Support and Training Program for Translational Research (TR), which was initiated by the Ministry of Education, Culture, Sports, Science and Technology, was launched in 2007. In its instructions, 2 clinical trial launches at each TR center in accordance with the Pharmaceutical Affairs Law was set as the goal. As a consequence of each center's intense effort on infrastructure development, as of January 2013, 18 IND (Investigational New Drug) trials are ongoing and 3 products obtained approvals and are already available. Another 4 seeds are under review by the authority, and will be approved soon. Thus the major universities in Japan have become capable of implementing drug & device development in accordance with the international rules, or stated another way, with the Pharmaceutical Affairs Law. This means that the R&D pipeline in academia has now been established. The system development has progressed to the point where new drug & device seeds are seamlessly becoming ready for clinical trials. Therefore, we will be able to decide on appropriate investment strategies by simulating how much time and money should be spent on which seeds/items development to achieve the targeted benefit to citizens from now on. The next steps are to consolidate this pipeline, evolve it further, and then globalize it. Hence the Ministry launched this subsequent program, the Translational Research Network Program, in the FY2012. The target was set higher and each center has been working on strengthening its management accordingly. The stage that is to be achieved at the end of this program will be the world's pre-eminent example of an outstanding Life-Innovation University Hospital Alliance.

### Key words

innovation, translational research (TR), drug & device development, clinical trial, network

*Rinsho Hyoka (Clinical Evaluation)* 2013 ; 41 : 5-150.